Skip to main content
. 2018 Oct 26;34(1):117–123. doi: 10.1080/14756366.2018.1532419

Figure 1.

Figure 1.

SLC-0111 sensitises melanoma cells to Dacarbazine and Temozolomide treatment. (a) Representative plots of Annexin V/PI assay of A375-M6 treated for 96 h with either 50 µM Dacarbazine, or 100 µM SLC-0111, or the combination of the two (lower) and relative quantification chart of early apoptosis, late apoptosis and necrosis ratio (upper). ***p < 0.001 Two-way ANOVA, N = 3. (b) Representative plots of Annexin V/PI assay of A375-M6 treated for 72 h with either 170 µM Temozolomide, or 100 µM SLC-0111, or the combination of the two (lower), and relative quantification chart of early apoptosis, late apoptosis, and necrosis ratio (upper). ***p < 0.001 Two-way ANOVA, N = 3. (c) Quantification chart of Trypan Blue exclusion assay of A375-M6 treated for 72 h with either 170 µM Temozolomide, or 100 µM SLC-0111, or the combination of the two. ***p < 0.001 One-way ANOVA, N = 3. (d) Quantification chart (upper) and representative image (lower) of western blot analysis of cleaved caspase 3 of A375-M6 treated 72 h with 170 µM Temozolomide and 100 µM SLC-0111 alone or combined. Tubulin used as loading control. ***p < 0.001, Two-way ANOVA, N = 3. (e) Quantification chart (upper) and representative pictures (lower) of colony formation assay of A375-M6 treated for 14 days with 170 µM Temozolomide and 100 µM SLC-0111 alone or in combination. *p < 0.05, One-way ANOVA, N = 3. (f) Chemical structure of SLC-0111.